Abstract
This study investigated the correlation between changes in hepatic hemodynamics and esophageal variceal pressure - measured with a noninvasive, pressure-sensitive endoscopie gauge - in 37 portal-hypertensive cirrhotic patients receiving propranolol (0.15 mg/kg, intravenously; n = 21) or placebo (n = 16) under strict double-blind conditions. Placebo administration had no effect on hepatic venous pressure gradient, azygos blood flow or variceal pressure. Propranolol caused a significant reduction in hepatic venous pressure gradient (from 19.6 ± 1 to 17.3 ± I mm Hg, p <0.001), azygos blood flow (from 0.61 ± 0.06 to 0.39 ± 0.03 L/min, p <0.001) and variceal pressure (from 13.1 ± 0.9 to 10.2 ± 0.9 mm Hg, p <0.001). In eight patients (propranolol nonresponders) hepatic venous pressure gradient was not modified or decreased by less than 10% after propranolol (mean change, -4.1 ± 1.6%). However, we found no significant differences between propranolol responders and nonresponders with regard to the decrease in variceal pressure (3.3 ± 0.7 vs. 2.3 ± 1.4 mm Hg) and azygos blood flow (0.23 ± 0.07 vs. 0.21 ± 0.07 L/min). As expected, in most propranolol responders (11 of 13), reduction in hepatic venous pressure gradient was accompanied by a similar response in variceal pressure (> 10% decrease). However, among propranolol nonresponders, in terms of reduction in hepatic venous pressure gradient, four out of eight patients had decreases greater than 10% in variceal pressure. The results of this study confirm that reduction in hepatic venous pressure gradient by propranolol is associated with a significant decrease in variceal pressure and azygos blood flow. These favorable effects are also observed in some patients in whom hepatic venous pressure gradient fails to decrease by more than 10% of the baseline value, suggesting that propranolol administration has beneficial effects in some of these patients.
| Original language | English |
|---|---|
| Pages (from-to) | 1082-1089 |
| Number of pages | 8 |
| Journal | Hepatology |
| Volume | 18 |
| Issue number | 5 |
| Publication status | Published - Nov 1993 |
Fingerprint
ASJC Scopus subject areas
- Hepatology
Cite this
Reduction of variceal pressure by propranolol : Comparison of the effects on portal pressure and azygos blood flow in patients with cirrhosis. / Feu, Faust; Bordas, Josep María; Luca, Angelo; García-Pagán, Joan Carles; Escorsell, Angels; Bosch, Jaume; Rodés, Joan.
In: Hepatology, Vol. 18, No. 5, 11.1993, p. 1082-1089.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Reduction of variceal pressure by propranolol
T2 - Comparison of the effects on portal pressure and azygos blood flow in patients with cirrhosis
AU - Feu, Faust
AU - Bordas, Josep María
AU - Luca, Angelo
AU - García-Pagán, Joan Carles
AU - Escorsell, Angels
AU - Bosch, Jaume
AU - Rodés, Joan
PY - 1993/11
Y1 - 1993/11
N2 - This study investigated the correlation between changes in hepatic hemodynamics and esophageal variceal pressure - measured with a noninvasive, pressure-sensitive endoscopie gauge - in 37 portal-hypertensive cirrhotic patients receiving propranolol (0.15 mg/kg, intravenously; n = 21) or placebo (n = 16) under strict double-blind conditions. Placebo administration had no effect on hepatic venous pressure gradient, azygos blood flow or variceal pressure. Propranolol caused a significant reduction in hepatic venous pressure gradient (from 19.6 ± 1 to 17.3 ± I mm Hg, p <0.001), azygos blood flow (from 0.61 ± 0.06 to 0.39 ± 0.03 L/min, p <0.001) and variceal pressure (from 13.1 ± 0.9 to 10.2 ± 0.9 mm Hg, p <0.001). In eight patients (propranolol nonresponders) hepatic venous pressure gradient was not modified or decreased by less than 10% after propranolol (mean change, -4.1 ± 1.6%). However, we found no significant differences between propranolol responders and nonresponders with regard to the decrease in variceal pressure (3.3 ± 0.7 vs. 2.3 ± 1.4 mm Hg) and azygos blood flow (0.23 ± 0.07 vs. 0.21 ± 0.07 L/min). As expected, in most propranolol responders (11 of 13), reduction in hepatic venous pressure gradient was accompanied by a similar response in variceal pressure (> 10% decrease). However, among propranolol nonresponders, in terms of reduction in hepatic venous pressure gradient, four out of eight patients had decreases greater than 10% in variceal pressure. The results of this study confirm that reduction in hepatic venous pressure gradient by propranolol is associated with a significant decrease in variceal pressure and azygos blood flow. These favorable effects are also observed in some patients in whom hepatic venous pressure gradient fails to decrease by more than 10% of the baseline value, suggesting that propranolol administration has beneficial effects in some of these patients.
AB - This study investigated the correlation between changes in hepatic hemodynamics and esophageal variceal pressure - measured with a noninvasive, pressure-sensitive endoscopie gauge - in 37 portal-hypertensive cirrhotic patients receiving propranolol (0.15 mg/kg, intravenously; n = 21) or placebo (n = 16) under strict double-blind conditions. Placebo administration had no effect on hepatic venous pressure gradient, azygos blood flow or variceal pressure. Propranolol caused a significant reduction in hepatic venous pressure gradient (from 19.6 ± 1 to 17.3 ± I mm Hg, p <0.001), azygos blood flow (from 0.61 ± 0.06 to 0.39 ± 0.03 L/min, p <0.001) and variceal pressure (from 13.1 ± 0.9 to 10.2 ± 0.9 mm Hg, p <0.001). In eight patients (propranolol nonresponders) hepatic venous pressure gradient was not modified or decreased by less than 10% after propranolol (mean change, -4.1 ± 1.6%). However, we found no significant differences between propranolol responders and nonresponders with regard to the decrease in variceal pressure (3.3 ± 0.7 vs. 2.3 ± 1.4 mm Hg) and azygos blood flow (0.23 ± 0.07 vs. 0.21 ± 0.07 L/min). As expected, in most propranolol responders (11 of 13), reduction in hepatic venous pressure gradient was accompanied by a similar response in variceal pressure (> 10% decrease). However, among propranolol nonresponders, in terms of reduction in hepatic venous pressure gradient, four out of eight patients had decreases greater than 10% in variceal pressure. The results of this study confirm that reduction in hepatic venous pressure gradient by propranolol is associated with a significant decrease in variceal pressure and azygos blood flow. These favorable effects are also observed in some patients in whom hepatic venous pressure gradient fails to decrease by more than 10% of the baseline value, suggesting that propranolol administration has beneficial effects in some of these patients.
UR - http://www.scopus.com/inward/record.url?scp=0027378835&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027378835&partnerID=8YFLogxK
M3 - Article
VL - 18
SP - 1082
EP - 1089
JO - Hepatology
JF - Hepatology
SN - 0270-9139
IS - 5
ER -